https://scholars.lib.ntu.edu.tw/handle/123456789/638372
標題: | A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B | 作者: | Yuen, Man-Fung Chen, Chi-Yi CHUN-JEN LIU Jeng, Wen-Juei Elkhashab, Magdy Coffin, Carla S Kim, Won Greenbloom, Susan Ramji, Alnoor Lim, Young S Kim, Yoon J Fung, Scott K Kim, Dong J Jang, Jeong-Won Lee, Kwan Sik Iyer, Radhakrishnan P Macfarlane, Chelsea Jackson, Kathy Locarnini, Stephen A Chan, Henry L Y Afdhal, Nezam H |
關鍵字: | HBV DNA suppression; HBsAg level; Inarigivir; retinoic acid-inducible gene 1; tenofovir | 公開日期: | 一月-2023 | 卷: | 43 | 期: | 1 | 來源出版物: | Liver international : official journal of the International Association for the Study of the Liver | 摘要: | Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed to determine the safety and efficacy of Inarigivir for the treatment of HBV infection. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638372 | ISSN: | 14783223 | DOI: | 10.1111/liv.15465 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。